Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness

Christian Taube, Jerry A. Nick, Britta Siegmund, Catherine Duez, Katsuyuki Takeda, Yeong Ho Rha, Jung Won Park, Anthony Joetham, Katie Poch, Azzeddine Dakhama, Charles A. Dinarello, Erwin W. Gelfand

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The effect of modifying early neutrophil-mediated inflammation on the development of airway hyperresponsiveness (AHR) was investigated using an interleukin (IL)-1 receptor antagonist (IL-1Ra), an anti-IL-18 antibody (anti-IL-18) or a p38 mitogen-activated protein kinase (MAPK) inhibitor (M39). Balb/c mice were sensitized to ovalbumin (OVA) and challenged with a single intranasal dose of OVA. Treatment with the IL-1Ra or anti-IL-18 was initiated 20 min before challenge, whereas M39 was administered 4 h before the challenge. Eight hours after challenge, sensitized mice showed significantly higher numbers of neutrophils in bronchoalveolar lavage (BAL) fluid; treatment with IL-1Ra, anti-IL-18, or M39 significantly decreased the influx of neutrophils. At 48 h, none of the treatments affected eosinophil inflammation in BAL fluid and lung tissue, goblet cell hyperplasia, or cytokine levels (IL-4, IL-5, IL-12, IL-13, interferon-γ) in BAL fluid. Anti-IL-18 or IL-1Ra had no effect on the development of AHR, whereas M39-treated mice showed a decrease in methacholine responsiveness. These results demonstrate that early neutrophil influx following allergen challenge is mediated by IL-1, IL-18, and p38 MAPK. However, neutralization of IL-1 and IL-18 did not affect the later development of AHR and eosinophilic airway inflammation. The effects of inhibiting p38 MAPK in decreasing AHR indicate activities independent of its prevention of neutrophil accumulation.

Original languageEnglish
Pages (from-to)837-843
Number of pages7
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume30
Issue number6
DOIs
Publication statusPublished - 2004 Jun 1

Fingerprint

Interleukin-18
Neutrophils
Interleukins
Bronchoalveolar Lavage Fluid
p38 Mitogen-Activated Protein Kinases
Ovalbumin
Inflammation
Interleukin-1
Fluids
Goblet Cells
Interleukin-1 Receptors
Interleukin-13
Methacholine Chloride
Interleukin-5
Interleukin-12
Protein Kinase Inhibitors
Eosinophils
Interleukin-4
Allergens
Interferons

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Taube, Christian ; Nick, Jerry A. ; Siegmund, Britta ; Duez, Catherine ; Takeda, Katsuyuki ; Rha, Yeong Ho ; Park, Jung Won ; Joetham, Anthony ; Poch, Katie ; Dakhama, Azzeddine ; Dinarello, Charles A. ; Gelfand, Erwin W. / Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness. In: American Journal of Respiratory Cell and Molecular Biology. 2004 ; Vol. 30, No. 6. pp. 837-843.
@article{1e909cb07c4d4547a00d374e6b17fab2,
title = "Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness",
abstract = "The effect of modifying early neutrophil-mediated inflammation on the development of airway hyperresponsiveness (AHR) was investigated using an interleukin (IL)-1 receptor antagonist (IL-1Ra), an anti-IL-18 antibody (anti-IL-18) or a p38 mitogen-activated protein kinase (MAPK) inhibitor (M39). Balb/c mice were sensitized to ovalbumin (OVA) and challenged with a single intranasal dose of OVA. Treatment with the IL-1Ra or anti-IL-18 was initiated 20 min before challenge, whereas M39 was administered 4 h before the challenge. Eight hours after challenge, sensitized mice showed significantly higher numbers of neutrophils in bronchoalveolar lavage (BAL) fluid; treatment with IL-1Ra, anti-IL-18, or M39 significantly decreased the influx of neutrophils. At 48 h, none of the treatments affected eosinophil inflammation in BAL fluid and lung tissue, goblet cell hyperplasia, or cytokine levels (IL-4, IL-5, IL-12, IL-13, interferon-γ) in BAL fluid. Anti-IL-18 or IL-1Ra had no effect on the development of AHR, whereas M39-treated mice showed a decrease in methacholine responsiveness. These results demonstrate that early neutrophil influx following allergen challenge is mediated by IL-1, IL-18, and p38 MAPK. However, neutralization of IL-1 and IL-18 did not affect the later development of AHR and eosinophilic airway inflammation. The effects of inhibiting p38 MAPK in decreasing AHR indicate activities independent of its prevention of neutrophil accumulation.",
author = "Christian Taube and Nick, {Jerry A.} and Britta Siegmund and Catherine Duez and Katsuyuki Takeda and Rha, {Yeong Ho} and Park, {Jung Won} and Anthony Joetham and Katie Poch and Azzeddine Dakhama and Dinarello, {Charles A.} and Gelfand, {Erwin W.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1165/rcmb.2003-0395OC",
language = "English",
volume = "30",
pages = "837--843",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "6",

}

Taube, C, Nick, JA, Siegmund, B, Duez, C, Takeda, K, Rha, YH, Park, JW, Joetham, A, Poch, K, Dakhama, A, Dinarello, CA & Gelfand, EW 2004, 'Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness', American Journal of Respiratory Cell and Molecular Biology, vol. 30, no. 6, pp. 837-843. https://doi.org/10.1165/rcmb.2003-0395OC

Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness. / Taube, Christian; Nick, Jerry A.; Siegmund, Britta; Duez, Catherine; Takeda, Katsuyuki; Rha, Yeong Ho; Park, Jung Won; Joetham, Anthony; Poch, Katie; Dakhama, Azzeddine; Dinarello, Charles A.; Gelfand, Erwin W.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 30, No. 6, 01.06.2004, p. 837-843.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness

AU - Taube, Christian

AU - Nick, Jerry A.

AU - Siegmund, Britta

AU - Duez, Catherine

AU - Takeda, Katsuyuki

AU - Rha, Yeong Ho

AU - Park, Jung Won

AU - Joetham, Anthony

AU - Poch, Katie

AU - Dakhama, Azzeddine

AU - Dinarello, Charles A.

AU - Gelfand, Erwin W.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - The effect of modifying early neutrophil-mediated inflammation on the development of airway hyperresponsiveness (AHR) was investigated using an interleukin (IL)-1 receptor antagonist (IL-1Ra), an anti-IL-18 antibody (anti-IL-18) or a p38 mitogen-activated protein kinase (MAPK) inhibitor (M39). Balb/c mice were sensitized to ovalbumin (OVA) and challenged with a single intranasal dose of OVA. Treatment with the IL-1Ra or anti-IL-18 was initiated 20 min before challenge, whereas M39 was administered 4 h before the challenge. Eight hours after challenge, sensitized mice showed significantly higher numbers of neutrophils in bronchoalveolar lavage (BAL) fluid; treatment with IL-1Ra, anti-IL-18, or M39 significantly decreased the influx of neutrophils. At 48 h, none of the treatments affected eosinophil inflammation in BAL fluid and lung tissue, goblet cell hyperplasia, or cytokine levels (IL-4, IL-5, IL-12, IL-13, interferon-γ) in BAL fluid. Anti-IL-18 or IL-1Ra had no effect on the development of AHR, whereas M39-treated mice showed a decrease in methacholine responsiveness. These results demonstrate that early neutrophil influx following allergen challenge is mediated by IL-1, IL-18, and p38 MAPK. However, neutralization of IL-1 and IL-18 did not affect the later development of AHR and eosinophilic airway inflammation. The effects of inhibiting p38 MAPK in decreasing AHR indicate activities independent of its prevention of neutrophil accumulation.

AB - The effect of modifying early neutrophil-mediated inflammation on the development of airway hyperresponsiveness (AHR) was investigated using an interleukin (IL)-1 receptor antagonist (IL-1Ra), an anti-IL-18 antibody (anti-IL-18) or a p38 mitogen-activated protein kinase (MAPK) inhibitor (M39). Balb/c mice were sensitized to ovalbumin (OVA) and challenged with a single intranasal dose of OVA. Treatment with the IL-1Ra or anti-IL-18 was initiated 20 min before challenge, whereas M39 was administered 4 h before the challenge. Eight hours after challenge, sensitized mice showed significantly higher numbers of neutrophils in bronchoalveolar lavage (BAL) fluid; treatment with IL-1Ra, anti-IL-18, or M39 significantly decreased the influx of neutrophils. At 48 h, none of the treatments affected eosinophil inflammation in BAL fluid and lung tissue, goblet cell hyperplasia, or cytokine levels (IL-4, IL-5, IL-12, IL-13, interferon-γ) in BAL fluid. Anti-IL-18 or IL-1Ra had no effect on the development of AHR, whereas M39-treated mice showed a decrease in methacholine responsiveness. These results demonstrate that early neutrophil influx following allergen challenge is mediated by IL-1, IL-18, and p38 MAPK. However, neutralization of IL-1 and IL-18 did not affect the later development of AHR and eosinophilic airway inflammation. The effects of inhibiting p38 MAPK in decreasing AHR indicate activities independent of its prevention of neutrophil accumulation.

UR - http://www.scopus.com/inward/record.url?scp=2942514690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942514690&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2003-0395OC

DO - 10.1165/rcmb.2003-0395OC

M3 - Article

C2 - 14742296

AN - SCOPUS:2942514690

VL - 30

SP - 837

EP - 843

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 6

ER -